ZYME logo

ZYME Zymeworks Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$26.86
+0.82 (+3.15%)

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the bilia…

Market Cap: $1.87Bwww.zymeworks.com

Price

No data yet.

Social Signal Score

42
5d
50
1 mentions
—
30d
34
5 mentions
—
60d
42
11 mentions
—
90d
44
14 mentions
—
news: 14

Analyst Ratings

23 analysts
Buyconsensus
Strong Buy 0Buy 21Hold 2Sell 0Strong Sell 0
Avg price target$42.71+59.0%
Low $32Median $40High $55
Current Consensus

Revenue

$256.46M+11390.14%
$40.0K$134.19M$268.34M$402.49M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.95
$-1.19–$-0.48
8 analysts
FY2026
$1.27
$0.82–$1.90
7 analysts
FY2027
$0.69-46% YoY
$-3.39–$6.69
8 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Kenneth H. Galbraith
Sector
Healthcare
Industry
Biotechnology
Employees
279
Beta
1.17
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
0.72
www.zymeworks.com